novo glp-1 drug Nordisk Expands Access Through Telehealth Providers Novo inks Ascendis deal to
Description
doi:10.1007/s00125-007-0692-2 58
doi: 10.1111/dom.13137 [DOI] [PubMed] [Google Scholar] 34
In the absence of robust, high-quality evidence, clinical decisions should be guided by individual risk assessment and shared decision-making
For example, when GLP-1 agonists were compared with the sulfonylurea, DPP4, and SGLT2 classes outcomes were improved in 13.14%, 17.14%, and 11.43% of the outcomes respectively
N Engl J Med 2021;384:1113-1124
